Pure Bioscience, Inc. Files 10-Q for Period Ending January 31, 2024

TL;DR

<b>Pure Bioscience, Inc. has filed its Q2 2024 10-Q report, detailing financial data and segment performance.</b>

AI Summary

PURE BIOSCIENCE, INC. (PURE) filed a Quarterly Report (10-Q) with the SEC on March 18, 2024. Pure Bioscience, Inc. filed a 10-Q report for the period ending January 31, 2024. The filing covers the second quarter of fiscal year 2024. The company's fiscal year ends on July 31st. The filing includes data related to common stock, additional paid-in capital, and retained earnings as of various dates. Specific product and royalty data for different periods are also included.

Why It Matters

For investors and stakeholders tracking PURE BIOSCIENCE, INC., this filing contains several important signals. This 10-Q filing provides investors with the latest financial performance and operational details for Pure Bioscience, Inc. for the second quarter of fiscal year 2024. The detailed segment information, including product and royalty data, allows for an assessment of the company's revenue streams and business focus.

Risk Assessment

Risk Level: low — PURE BIOSCIENCE, INC. shows low risk based on this filing. The filing is a standard 10-Q, providing routine financial updates without immediate red flags, indicating a low level of immediate risk from this specific filing.

Analyst Insight

Review the detailed segment data for product and royalty performance to understand revenue drivers and potential growth areas.

Revenue Breakdown

Key Numbers

• 2024-01-31 — Reporting Period End Date (Conformed Period of Report)
• 2024-03-18 — Filing Date (Filed as of Date)
• 0731 — Fiscal Year End (Fiscal Year End)
• Q2 — Quarter (Filing Values)

Key Players & Entities

• PURE BIOSCIENCE, INC. (company) — Filer name
• 0001006028 (company) — Central Index Key
• 2890 (regulator) — Standard Industrial Classification Code
• DE (company) — State of Incorporation
• 771 JAMACHA ROAD #512 (company) — Business Address Street 1
• EL CAJON (company) — Business Address City
• 92019 (company) — Business Address ZIP
• 619-596-8600 (company) — Business Phone

FAQ

Key Dates

• 2024-01-31: Quarter End Date — End of the reporting period for the 10-Q filing.

Key Financial Figures

• $0.01 — ction 12(g) of the Act: Common Stock, $0.01 par value Indicate by check mark whet
• $0.15 — that such conversion price is at least $0.15 per share and less than or equal to $0.
• $0.23 — .15 per share and less than or equal to $0.23 per share, subject to certain customary

Filing Documents

• form10-q.htm (10-Q) — 568KB
• ex31-1.htm (EX-31.1) — 19KB
• ex31-2.htm (EX-31.2) — 19KB
• ex32-1.htm (EX-32.1) — 9KB
• ex32-2.htm (EX-32.2) — 9KB
• 0001493152-24-010313.txt (&nbsp;) — 3116KB
• pure-20240131.xsd (EX-101.SCH) — 20KB
• pure-20240131_cal.xml (EX-101.CAL) — 31KB
• pure-20240131_def.xml (EX-101.DEF) — 111KB
• pure-20240131_lab.xml (EX-101.LAB) — 210KB
• pure-20240131_pre.xml (EX-101.PRE) — 167KB
• form10-q_htm.xml (XML) — 381KB

Financial Statements

Financial Statements 3 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 15 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 22 Item 4.

Controls and Procedures

Controls and Procedures 22 PART II OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 23 Item 1A.

Risk Factors

Risk Factors 23 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 24 Item 3. Defaults Upon Senior Securities 24 Item 4. Mine Safety Disclosures 24 Item 5. Other Information 24 Item 6. Exhibits 25

Signatures

Signatures 26 2 Part I - Financial Information Item 1. Financial Statements PURE Bioscience, Inc. Condensed Consolidated Balance Sheets January 31, 2024 July 31, 2023 (Unaudited) Assets Current assets Cash and cash equivalents $ 557,000 $ 1,095,000 Accounts receivable 171,000 285,000 Inventories, net 74,000 88,000 Restricted cash 75,000 75,000 Prepaid expenses 62,000 61,000 Total current assets 939,000 1,604,000 Property, plant and equipment, net 147,000 221,000 Total assets $ 1,086,000 $ 1,825,000 Liabilities and stockholders' equity (deficiency) Current liabilities Accounts payable $ 409,000 $ 422,000 Accrued liabilities 136,000 110,000 Total current liabilities 545,000 532,000 Long-term liabilities Note payable to related parties 1,862,000 1,021,000 Total long-term liabilities 1,862,000 1,021,000 Total liabilities 2,407,000 1,553,000 Commitments and contingencies - - Stockholders' equity (deficiency) Preferred stock, $ 0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding — — Common stock, $ 0.01 par value: 150,000,000 shares authorized, 111,856,473 shares issued and outstanding at January 31, 2024, and July 31, 2023 1,119,000 1,119,000 Additional paid-in capital 132,542,000 132,398,000 Accumulated deficit ( 134,982,000 ) ( 133,245,000 ) Total stockholders' equity (deficiency) ( 1,321,000 ) 272,000 Total liabilities and stockholders' equity (deficiency) $ 1,086,000 $ 1,825,000 See accompanying notes. 3 PURE Bioscience, Inc. Condensed Consolidated Statements of Operations (Unaudited) 2024 2023 2024 2023 Six Months Ended Three months Ended January 31, January 31, 2024 2023 2024 2023 Net product sales $ 1,043,000 $ 863,000 $ 325,000 $ 396,000 Royalty revenue 5,000 5,000 1,000 1,000 Total revenue 1,048,000 868,000 326,000 397,000 Cost of goods sold 429,000 414,000 149,000 200,000 Gr

View Full Filing

View this 10-Q filing on SEC EDGAR